• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Metformin, ivermectin, and fluvoxamine do not prevent severe SARS-CoV-2 infection

byAndrew LeeandKiera Liblik
August 26, 2022
in Emergency, Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Metformin, ivermectin, and fluvoxamine do not prevent hypoxemia, emergency department visits, hospitalization, or death in coronavirus disease 2019 (COVID-19) patients.

2. Patients in the treatment groups did not experience a significant reduction in overall symptoms or COVID-19-related symptoms compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The COVID-19 pandemic has resulted in significant morbidity and mortality globally since it began in 2019. Yet, there are currently very limited options for COVID-19 outpatient treatments. Based on their biophysical profiles, it has been hypothesized that metformin, ivermectin, and fluvoxamine could be deleterious to different elements of viral replication and inflammatory responses which contribute to COVID-19 severity. In the present trial, these therapeutic agents were compared to a placebo control in COVID-19 patients. Overall, there was no significant effect on hypoxemia, emergency department visits, hospitalization, or death by any of the three trial medications. This lack of effect was consistently observed in all subgroup analyses, as well. On self-reported symptom scales, none of the trial drugs reduced symptoms faster than the placebo control. A pertinent study limitation is the narrow study population, which was limited to those between 30 and 85 years old as well as those who were obese or overweight. The strength of this study was that it examined both subjective and objective measures of disease severity and impact.

Click to read the study in NEJM

Relevant Reading: Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce

RELATED REPORTS

Trimethoprim-sulfamethoxazole during pregnancy does not reduce risk of prematurity

Second-line TAF-based ART improves viral suppression in pediatric HIV

Midlife weight loss is associated with decreased risk of mortality and chronic disease

In-Depth [randomized control trial]: The present phase three, double-blinded, randomized controlled trial examined the effectiveness of three therapeutic agents (metformin, ivermectin, and fluvoxamine) in preventing serious or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Eligibility criteria included individuals aged 30 to 85 years, a body-mass index in the overweight or obese category, confirmed SARS-CoV-2 infection within the past three days, and symptoms within seven days of study randomization. Outcomes included hypoxemia, emergency department visits, hospitalization, or death. Additionally, self-reported generalized symptom and COVID-19-specific symptom scales were administered. Individuals were randomized into one of six groups, which were combinations of two of the trial drugs as well as a placebo control. A total of 1,323 patients were enrolled in the study and subsequently included in the primary analysis. The adjusted odds ratio for a primary event was 0.84 (95% Confidence Interval [CI], 0.66 to 1.09; p=0.19) with metformin, 1.05 (95% CI, 0.76 to 1.45; p=0.78) with ivermectin, and 0.94 (95% CI, 0.66 to 1.36; p=0.75). Hospitalization or death occurred in eight of 596 patients (1.3%) in the metformin group and 19 of 601 patients (3.2%) in the control group. None of the trial medications had an effect on self-reported symptoms related to COVID-19 or otherwise. No medication-related serious adverse events occurred during the study. In summary, the present study suggests that metformin, ivermectin, and fluvoxamine are not effective therapeutic agents for treating COVID-19.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Coronavirus disease 2019COVID-19 Treatmentemergencyfluvoxamineinfectious diseaseivermectinmetforminpublic healthSARS-CoV-2
Previous Post

Ensovibep not efficacious in treating hospitalized COVID-19 patients

Next Post

Youth-onset type 2 diabetes may have increased sharply during the COVID-19 pandemic

RelatedReports

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Infectious Disease

Trimethoprim-sulfamethoxazole during pregnancy does not reduce risk of prematurity

June 9, 2025
Government-funded initiatives provide important supports to low-income HIV patients
Infectious Disease

Second-line TAF-based ART improves viral suppression in pediatric HIV

June 4, 2025
Sleep duration inversely related to childhood type 2 diabetes risk makers
Chronic Disease

Midlife weight loss is associated with decreased risk of mortality and chronic disease

June 3, 2025
Chronic Disease

Incidence and prevalence of dementia among US Medicare beneficiaries between 2015 – 2021

May 31, 2025
Next Post
Pediatric DKA associated with recent acute care visits

Youth-onset type 2 diabetes may have increased sharply during the COVID-19 pandemic

Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities

Ublituximab lowers incidence of relapse and number of brain lesions in relapsing multiple sclerosis

2 Minute Medicine Rewind January 28, 2019

Olokizumab is noninferior to adalimumab for the treatment of rheumatoid arthritis

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravaginal conjugated oestrogen does not improve continuation rate of ring pessary use
  • Artificial intelligence based clinical decision systems are safe and effective for diabetes management
  • Epic Launchpad propels generative-AI into everyday hospital routines
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.